International Journal of Medical Laboratory Research (IJMLR)

EVALUATION OF MALARIA VACCINATION WITH RTS,S/AS01 (MOSQUIRIX™) AMONG CHILDREN ATTENDING TWO DISTRICT HOSPITALS IN THE CENTRAL REGION OF CAMEROON

 

Nfor Omarine Nlinwe, Tingwick Junior Mbah

​

ABSTRACT: Malaria is a major cause of illness and death among children under five in sub-Saharan Africa. Recent progress in vaccine development, including RTS,S/AS01 shows promise for disease control with encouraging efficacy and safety profiles. This cross-sectional study assessed malaria prevalence and vaccination coverage among children under five years in two district hospitals, Soa and Biyem-Assi, in the Central Region of Cameroon. Among 450 children, 19.56% (88/450) tested positive for malaria, while 47.11% (212/450) had received at least one malaria vaccine dose. Malaria prevalence was lower among vaccinated than unvaccinated children (13.21% vs. 25.21%; OR=0.45, 95% CI: 0.28–0.73; p=0.0013). Rural residence was associated with higher malaria prevalence (30.77% vs. 18.09% in urban areas; p=0.0302). Among vaccinated children, malaria was significantly associated with age, residence, household income, number of vaccine doses, and time since the last dose. In multivariable analysis, ≥3 vaccine doses were associated with lower odds of malaria infection (AOR=0.33, 95% CI: 0.19–0.57; p<0.001), while ≥3 months since the last dose was associated with higher odds (AOR=2.22, 95% CI: 1.52–3.25; p<0.001). Vaccination status itself was not significantly associated with malaria after adjustment (AOR=1.10, 95% CI: 0.29–4.15; p=0.886). Although vaccinated children had lower malaria prevalence in the crude analysis, vaccination status was not independently associated with malaria infection after adjustment. Completion of the recommended vaccine doses and timely receipt of subsequent doses were associated with lower malaria infection, highlighting the importance of maintaining the recommended vaccination schedule.

​

Keywords: Malaria; Malaria vaccine; Children; Soa District Hospital, Biyem-Assi District Hospital.

​

​

REFERENCE: 

1. Rosenthal PJ. Malaria in 2022: challenges and progress. The American Journal of Tropical Medicine and Hygiene. 2022;106(6):1565.

2. Datoo MS, Natama MH, Somé A, Traoré O, Rouamba T, Bellamy D, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. The Lancet. 2021;397(10287):1809-18.

3. Organization WH. WHO recommends groundbreaking malaria vaccine for children at risk. World Health Organization. 2021;1.

4. Mumtaz H, Nadeem A, Bilal W, Ansar F, Saleem S, Khan QA, et al. Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: a review. Immunity, Inflammation and Disease. 2023;11(6):e899.

5. Organization WH. WHO malaria policy advisory group (MPAG) meeting, October 2022: World Health Organization; 2022.

6. Samuels AM, Ansong D, Kariuki SK, Adjei S, Bollaerts A, Ockenhouse C, et al. Efficacy of RTS, S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial. The Lancet Infectious Diseases. 2022;22(9):1329-42.

7. Aremu TO, Ajibola OA, Oluwole OE, Adeyinka KO, Dada SO, Okoro ON. Looking beyond the malaria vaccine approval to acceptance and adoption in Sub-Saharan Africa. Frontiers in Tropical Diseases. 2022;3:857844.

8. Praet N, Asante KP, Bozonnat M-C, Akité EJ, Ansah PO, Baril L, et al. Assessing the safety, impact and effectiveness of RTS, S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up. Malaria Journal. 2022;21(1):132.

9. Syed YY. RTS, S/AS01 malaria vaccine (Mosquirix®): a profile of its use. Drugs & Therapy Perspectives. 2022;38(9):373-81.

10. Nadeem A, Shehzad A, Islam S, Al-Suhaimi E, Lee Y. Mosquirix™ RTS, S/AS01 vaccine development, immunogenicity, and efficacy. Vaccines 2022; 10: 713. s Note: MDPI stays neutral with regard to jurisdictional claims in published …; 2022.

11. Parums DV. current status of two adjuvanted malaria vaccines and the World Health Organization (WHO) strategy to eradicate malaria by 2030. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2023;28:e939357-1.

12. Nadeem AY, Shehzad A, Islam SU, Al-Suhaimi EA, Lee YS. Mosquirix™ RTS, S/AS01 vaccine development, immunogenicity, and efficacy. Vaccines. 2022;10(5):713.

13. Osoro CB, Ochodo E, Kwambai TK, Otieno JA, Were L, Sagam CK, et al. Policy uptake and implementation of the RTS, S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation. BMJ Global Health. 2024;9(4).

14. Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M, et al. Seven-year efficacy of RTS, S/AS01 malaria vaccine among young African children. New England Journal of Medicine. 2016;374(26):2519-29.

15. Moorthy V, Hamel MJ, Smith PG. Malaria vaccines for children: and now there are two. The Lancet. 2024;403(10426):504-5.

16. Dicko A, Ouedraogo J-B, Zongo I, Sagara I, Cairns M, Yerbanga RS, et al. Seasonal vaccination with RTS, S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. The Lancet Infectious Diseases. 2024;24(1):75-86.

17. Bam V, Mohammed A, Kusi-Amponsah A, Armah J, Lomotey AY, Budu HI, et al. Caregivers’ perception and acceptance of malaria vaccine for Children. PLoS One. 2023;18(7):e0288686.

18. Saaka SA, Mohammed K, KA Pienaah C, Luginaah I. Child malaria vaccine uptake in Ghana: Factors influencing parents’ willingness to allow vaccination of their children under five (5) years. Plos one. 2024;19(1):e0296934.

19. Chutiyami M, Saravanakumar P, Bello UM, Salihu D, Adeleye K, Kolo MA, et al. Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies. Infection. 2024;52(5):2007-28.

20. Amin MA, Afrin S, Bonna AS, Rozars MFK, Nabi MH, Hawlader MDH. Knowledge and acceptance of malaria vaccine among parents of under‐five children of malaria endemic areas in Bangladesh: A cross‐sectional study. Health Expectations. 2023;26(6):2630-43.

21. Ndoula ST, Mboussou F, Njoh AA, Nembot R, Baonga SF, Njinkeu A, et al. Malaria vaccine introduction in Cameroon: early results 30 days into rollout. Vaccines. 2024;12(4):346.

22. Azakoh J, Defo Tamgno E, Ifang S. Assessment of The Acceptance of The RTS, S/AS01 Malaria Vaccine By Parents of Children Under Five Years of age in the Foumbot and Foumban Health Districts in Cameroon. JM Med Stu. 2024;1(1):13-9.​

23. Ghoutum A, Edith KW, Lebga AK. Landfill site suitability selection using geospatial technology for the Yaounde metropolitan city and its environs: case of Soa subdivision, Cameroon. European Scientific Journal. 2020;16(6):95-111.

24. Alain DC, Nghonjuyi NW, Kindong NP. Knowledge of the Implementation of the Malaria Control Program in Four Health Districts in Yaounde, Cameroon. 2021.

25. Majale M, Mougoué B. Stocktaking of the Housing Sector in Sub-Saharan Africa Part 2: Cameroon. 2015.

26. DE LA VILLE DL. PROFIL ENVIRONNEMENTAL. 2002.

27. Defo Tamgno E, Tsapi Armand T, Fossi Tamgno M, Essofack Joseph N, Tamoufe Gaelle M, Vittorio C, et al. Epidemiological assessment of malaria prevalence among children under 5 in Cameroon: a cross-sectional study. Archives of Microbiology & Immunology. 2024;8(4).

28. Cunningham J, Jones S, Gatton ML, Barnwell JW, Cheng Q, Chiodini PL, et al. A review of the WHO malaria rapid diagnostic test product testing programme (2008–2018): performance, procurement and policy. Malaria journal. 2019;18(1):387.

29. Alum EU, Ainebyoona C, Egwu CO, Onohuean H, Ugwu OP-C, Uti DE, et al. Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication. Ethiopian Journal of Health Sciences. 2025;35(3).